153 related articles for article (PubMed ID: 31633393)
1. Overexpression of
Liu Z; Dang C; Xing E; Zhao M; Shi L; Sun J
DNA Cell Biol; 2019 Nov; 38(11):1366-1373. PubMed ID: 31633393
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a.
Li Y; Lv S; Ning H; Li K; Zhou X; Xv H; Wen H
Biomed Pharmacother; 2018 Dec; 108():1775-1782. PubMed ID: 30372881
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Growth-Arrest-Specific Transcript 5 Improved Cisplatin Sensitivity in Hepatocellular Carcinoma Through Sponging miR-222.
Zhao P; Cui X; Zhao L; Liu L; Wang D
DNA Cell Biol; 2020 Apr; 39(4):724-732. PubMed ID: 32213078
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
Wang J; Jia J; Zhou L
Neoplasma; 2020 Nov; 67(6):1279-1292. PubMed ID: 32787433
[TBL] [Abstract][Full Text] [Related]
5. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L
Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512
[TBL] [Abstract][Full Text] [Related]
6. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
[TBL] [Abstract][Full Text] [Related]
8. The Long Non-Coding RNA CASC2 Suppresses Cell Viability, Migration, and Invasion in Hepatocellular Carcinoma Cells by Directly Downregulating miR-183.
Sun J; Liu L; Zou H; Yu W
Yonsei Med J; 2019 Oct; 60(10):905-913. PubMed ID: 31538425
[TBL] [Abstract][Full Text] [Related]
9. Effect of lncRNA KCNQ1OT1 on autophagy and drug resistance of hepatocellular carcinoma cells by targeting miR-338-3p.
Zhong W; Dai Q; Huang Q
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):191-196. PubMed ID: 32538770
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-κB axis.
Zhao L; Zhang Y; Zhang Y
J Cell Physiol; 2018 Oct; 233(10):6661-6670. PubMed ID: 29319182
[TBL] [Abstract][Full Text] [Related]
11. Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma.
Zhang K; Shao CX; Zhu JD; Lv XL; Tu CY; Jiang C; Shang MJ
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32463473
[TBL] [Abstract][Full Text] [Related]
12. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
13. LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR-24-3p.
Fan JC; Zeng F; Le YG; Xin L
J Cell Biochem; 2018 Aug; 119(8):6391-6397. PubMed ID: 29091305
[TBL] [Abstract][Full Text] [Related]
14. miR-21-5p Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting FASLG.
Chen S; Yang C; Sun C; Sun Y; Yang Z; Cheng S; Zhuge B
DNA Cell Biol; 2019 Aug; 38(8):865-873. PubMed ID: 31225740
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
[TBL] [Abstract][Full Text] [Related]
16. lncRNA CASC2 Enhances
Tao L; Tian P; Yang L; Guo X
Biomed Res Int; 2020; 2020():7183629. PubMed ID: 33134385
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of cancer susceptibility candidate 2 inhibited progression of hepatocellular carcinoma cells.
Gao X; Du H; Zhang R; Li C; Wang H; Xuan Q; Liu D
J Cell Physiol; 2019 Jun; 234(6):9008-9018. PubMed ID: 30362539
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
Ou Y; Zhai D; Wu N; Li X
Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
[TBL] [Abstract][Full Text] [Related]
19. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p.
Cheng FH; Zhao ZS; Liu WD
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7256-7265. PubMed ID: 31539112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
